The OnKommon Precision Intelligence Platform.
Turning raw genomic signal into a decision a clinician can sign.
Behind every Blueprint Care report is the OnKommon Precision Intelligence Platform (OPIP) — our proprietary system for turning raw genomic signal into a decision a clinician can sign. It is not a single algorithm but a stack: an accredited generation layer, a curated knowledge substrate, a core interpretation engine, and six intelligence layers that go beyond what any public database can offer. Every output is traceable, versioned, and handed to a human for the final word.
The OnKommon Precision Intelligence Platform (OPIP).
A proprietary stack: accredited generation, curated knowledge, a core interpretation engine, and six intelligence layers.
- Accredited generation: NABL/CAP-standard laboratory partners
- Curated knowledge: OGID — OnKommon Gene Interpretation Database
- Core engine: Annotation, evidence tiering, and biomarker–drug–trial matching
- Six intelligence layers: CloneTrace™, SynerGx™, PhenoMap™, ImmunoLens™, TrialGraph™, AccessMatch™
- Human sign-out: KPCIRC molecular tumour board review
Generate. Interpret. Sign out.
Every output is traceable, versioned, and handed to a human for the final word.
Accredited Lab Partner
Accredited (NABL/CAP-standard) laboratory partners sequence the tumour from blood or tissue, with transparent quality control and per-gene coverage.
OnKommon Interpretation Engine
The OnKommon Interpretation Engine annotates every alteration, matches it to therapies and trials, and applies the six intelligence layers.
KPCIRC Molecular Tumour Board
KPCIRC's molecular tumour board reviews, adds clinical judgement, authors the narrative, and signs — producing the decision.
OGID — OnKommon Gene Interpretation Database.
Our curated, versioned knowledge graph harmonising the world's leading evidence standards into a single, auditable framework.
Annotation & Oncogenicity
Each variant is classified for its biological effect and cancer relevance.
Evidence Tiering
Clinical significance is graded against international frameworks.
Biomarker–Drug–Trial Matching
Actionable alterations are linked to therapies and recruiting studies.
Quality-Aware
Depth, tumour fraction, and coverage are carried through so results are read in context.
Beyond what any public database can offer.
Public databases can tell you what a variant is. They cannot tell you how a tumour will evolve, whether the immune system can see it, or which combination is worth the toxicity.
CloneTrace™
Clonal architecture & evolutionary forecasting. Reconstructs which mutations are founder events versus later subclonal branches.
SynerGx™
Multi-omic combination synergy. Scores rational drug combinations for genuine added benefit versus overlapping toxicity.
PhenoMap™
Molecular subtype classification. Places the tumour into its biological subtype, sharpening treatment selection and prognosis.
ImmunoLens™
Immune-evasion risk & immunotherapy response. Combines antigenicity with antigen-presentation integrity to estimate immunotherapy response.
TrialGraph™
Trial & "patient-like-me" matching. Matches the exact molecular profile to recruiting clinical trials.
AccessMatch™
Biosimilar, access & economics. Maps each recommended therapy to biosimilars, Patient Assistance Programmes, and schemes available in India.
Graded against the frameworks oncologists already trust.
OnKommon does not invent its own clinical significance scale. Every actionable variant is graded against the frameworks oncologists already trust, and where they differ, we show the disagreement.
AMP/ASCO/CAP Tiers
Clinical significance of somatic variants (Tier I–IV).
ESCAT
How ready a molecular target is to guide treatment.
OncoKB Levels
Therapeutic actionability by level of evidence.
Diagnostic assay versus research-use engine.
Precise about what is regulated and how.
The molecular assays (sequencing) are diagnostic laboratory tests performed to accredited standards; OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) devices with CDSCO is in progress (IVD class pending). The OnKommon interpretation engine and its intelligence layers are provided for research and decision-support use — they inform a clinician and are not themselves a registered diagnostic device. Clinical authority always rests with KPCIRC's licensed molecular tumour board.
The words you will see, in plain language.
What we DO
- Run accredited (CAP / ISO 15189) sequencing and variant calling
- Grade every variant against AMP/ASCO/CAP, ESCAT and OncoKB
- Version the knowledge base and state the version on every report
- Keep a licensed human (KPCIRC MTB) as the final authority
What we DON'T do
- Let software diagnose or prescribe
- Report a result without disclosing coverage, tumour fraction and limits
- Claim regulatory approvals we do not hold
- Use your data for research without separate, explicit consent
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →